C7, one of the components of the terminal complement complex (TCC), also know as the membrane attack complex (MAC). Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 MAC. This complex is assembled from five precursor molecules in the serum, finalized with the polymerization of C9 which accompanies insertion of the complex into the cell membrane causing cellular lysis. C7 occupies an important position in the TCC cascade. C7 undergoes a hydrophilic-amphiphilic transition following activation. It enables the developing MAC to bind directly to target cell membranes. C7 has been shown to exhibit genetic polymorphism. Polymorphonuclear leukocytes represent a major source of C7. The fact that inflammatory cells have the potential to secrete C7 suggests an important role for locally produced complement in the inflammatory process.

Suitable for use in Western Blot. Other applications not tested.

Optimal dilutions to be determined by the researcher.

Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight™650 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Note: Applications are based on unconjugated antibody.

C7 (NP_000578.2, 1-843aa) full-length human protein.

Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with MaxLight™650.

Purified.

Recognizes human C7. Species Crossreactivity: mouse.